Best hot flash treatments in 2026: the buyer’s shortlist

2. Veozah (fezolinetant), best for a non-hormone pill with the longest track record

Veozah (fezolinetant) was the first of a new class of non-hormone medicines, approved by the FDA in 2023 for moderate to severe hot flashes due to menopause. It blocks the neurokinin-3 receptor in the brain’s temperature-control center. It is a pill taken once a day, with or without food (FDA label).

In the 12-week SKYLIGHT 1 trial, fezolinetant reduced the number of moderate to severe hot flashes by about two more per day than placebo by week 4, with the benefit maintained at week 12 (Lederman 2023). The Menopause Society rates it as a recommended non-hormone option.

The main drawback is the liver. Veozah carries a boxed warning for liver injury reported after it reached the market. The label requires liver blood tests before you start, monthly for the first three months, and again at six and nine months, and it says not to start Veozah if certain liver values are already raised.

On cost, the maker’s savings page says commercially insured patients may pay $0 for the first month’s prescription and as little as $30 per monthly refill, up to $4,000 a year in assistance. The offer isn’t valid for cash-paying patients or government insurance, and uninsured women may qualify for a patient assistance program. Veozah suits women who can’t or won’t take hormones and can keep up with the blood tests.

Facts from veozah.com, as of October 2026.

3. Lynkuet (elinzanetant), best for night-time hot flashes without hormones

Lynkuet (elinzanetant) is the second neurokinin-blocking medicine for hot flashes. Bayer announced its FDA approval on October 24, 2025, for moderate to severe hot flashes due to menopause (Bayer). Unlike Veozah, it blocks both the neurokinin-1 and neurokinin-3 receptors, and it is taken as two capsules once a day at bedtime (FDA label).

In the OASIS 1 and 2 trials, which together enrolled about 800 postmenopausal women, elinzanetant reduced moderate to severe hot flashes by about three more per day than placebo at weeks 4 and 12, and also reduced their severity (Pinkerton 2024).

Lynkuet doesn’t have a boxed warning, but its label lists several cautions. It can cause sleepiness and daytime impairment, which is one reason it’s taken at bedtime. The label calls for liver tests before starting and three months later, warns that it may cause pregnancy loss, and since August 2026 includes a warning about seizure risk. Because it is so new, Lynkuet wasn’t part of The Menopause Society’s 2023 statement, and we couldn’t verify a price on the maker’s site.

Lynkuet may suit women who can’t take hormones and are bothered most by night sweats, as long as their clinician is comfortable prescribing a newer medicine and they can avoid driving if they feel drowsy.

Facts from dailymed.nlm.nih.gov, as of October 2026.

4. Low-dose paroxetine (Brisdelle), best for an older non-hormone option

Before the neurokinin blockers arrived, low-dose antidepressants were the main non-hormone prescription for hot flashes. Brisdelle is paroxetine, an SSRI, at a low dose made specifically for this use. Its FDA label covers moderate to severe hot flashes associated with menopause, and it is taken once a day at bedtime (FDA label). The label is clear that Brisdelle isn’t approved to treat depression or any other psychiatric condition.

The Menopause Society’s 2023 statement gives its highest rating to SSRIs and SNRIs as a group, along with gabapentin, for hot flashes (2023 position statement). Other medicines in these groups are often prescribed off-label for the same purpose. They tend to reduce hot flashes less than hormone therapy does.

Like all antidepressants, Brisdelle carries a boxed warning about suicidal thoughts and behaviors, mainly in younger people. Paroxetine also interacts with a number of medicines. In particular, it can reduce how well tamoxifen works, which matters for women who have had breast cancer, so tell your clinician about everything you take. Low-dose paroxetine or another SSRI or SNRI can make sense for women who can’t take hormones and want an established medicine with a long safety record, or who also struggle with low mood.

Facts from dailymed.nlm.nih.gov, as of October 2026.

5. CBT and clinical hypnosis, best for a drug-free approach

Cognitive behavioral therapy (CBT) for hot flashes is a short, structured program that teaches practical ways to manage them: paced breathing during a flash, changing the thoughts that make it more distressing, and improving sleep. Clinical hypnosis uses guided relaxation and mental imagery, such as imagining coolness. The Menopause Society’s 2023 statement gives both its highest level of recommendation (2023 position statement).

In the MENOS 2 trial, women who did group CBT or a self-help CBT book reported that their hot flashes and night sweats were significantly less of a problem at 6 weeks and 26 weeks than women who had no treatment. Night sweats also became less frequent, and mood and quality of life improved (Ayers 2012).

The trade-off is that CBT mostly changes how much hot flashes bother you, rather than how many you have. That still matters, because how much they bother you is a big part of what makes them worth treating. It has no drug side effects and can be combined with any other treatment on this list. Access can be the main barrier, but the self-help book version worked about as well as the group sessions in MENOS 2, which makes it easier to try at home. CBT and hypnosis suit women who want a drug-free option or extra help alongside medicine.

Facts from pubmed.ncbi.nlm.nih.gov, as of October 2026.

6. Black cohosh and soy supplements, best for women set on trying a supplement first

Black cohosh and soy are the most popular supplements for hot flashes, and we include them because so many women try them first. The evidence is weak. The Menopause Society’s 2023 statement does not recommend supplements and herbal remedies, soy foods, soy extracts or the soy metabolite equol for hot flashes (2023 position statement).

The NIH’s National Center for Complementary and Integrative Health summarizes black cohosh research as mixed: a 2023 review of 22 studies found it potentially beneficial for overall menopause symptoms, with improvements in hot flashes, but not for anxiety or depression. It also reports cases of liver damage, some very serious, in people taking black cohosh, and notes that some products have contained the wrong herb (NCCIH).

For soy, NCCIH says isoflavone supplements or soy protein may help reduce how often and how severely hot flashes happen, but that the effect may be small and the research hasn’t been consistent (NCCIH). Supplements aren’t checked by the FDA for effectiveness before sale, and quality varies between brands.

If your hot flashes are mild and you want to try a supplement first, choose a reputable brand, tell your doctor, and stop black cohosh if you notice signs of liver problems such as yellowing skin, dark urine or stomach pain. If supplements don’t help within a few months, the prescription options above have much stronger evidence.

Facts from nccih.nih.gov, as of October 2026.